Fulcrum Therapeutics Full Year 2024 Earnings: EPS Misses Expectations [Yahoo! Finance]
Fulcrum Therapeutics, Inc. (FULC)
Last fulcrum therapeutics, inc. earnings: 3/5 07:00 am
Check Earnings Report
Company Research
Source: Yahoo! Finance
Net loss: US$9.73m (loss narrowed by 90% from FY 2023). US$0.16 loss per share (improved from US$1.59 loss in FY 2023). NasdaqGM:FULC Earnings and Revenue History February 26th 2025 All figures shown in the chart above are for the trailing 12 month (TTM) period Fulcrum Therapeutics EPS Misses Expectations Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 6.7%. Looking ahead, revenue is expected to decline by 57% p.a. on average during the next 3 years, while revenues in the Pharmaceuticals industry in the US are expected to grow by 8.4%. Performance of the American Pharmaceuticals industry. The company's shares are down 1.9% from a week ago. Risk Analysis What about risks? Every company has them, and we've spotted 2 warning signs for Fulcrum Therapeutics (of which 1 can't be ignored!) you should know about. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, emai
Show less
Read more
Impact Snapshot
Event Time:
FULC
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
FULC alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
FULC alerts
High impacting Fulcrum Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
FULC
News
- Fulcrum Therapeutics (NASDAQ:FULC) was given a new $18.00 price target on by analysts at Truist Financial Corporation.MarketBeat
- Fulcrum Therapeutics Announces Pricing of Upsized $175.0 Million Public Offering of Common Stock and Pre-Funded WarrantsGlobeNewswire
- Fulcrum Therapeutics (NASDAQ:FULC) had its price target raised by analysts at Bank of America Corporation from $6.00 to $7.00. They now have an "underperform" rating on the stock.MarketBeat
- Fulcrum Therapeutics Announces Proposed $150.0 Million Public Offering of Common StockGlobeNewswire
- Fulcrum Therapeutics (NASDAQ:FULC) was given a new $25.00 price target on by analysts at Stifel Nicolaus.MarketBeat
FULC
Earnings
- 10/29/25 - Miss
FULC
Sec Filings
- 12/15/25 - Form 144
- 12/11/25 - Form 8-K
- 12/11/25 - Form 424B5
- FULC's page on the SEC website